Regeneron-1787 (Cutaneous Squamous Cell Carcinoma) - Clinical Trial

Call to Participate

What is the Purpose of this Study?

Treatment

We are doing the study to understand how your body reacts to the study drug, Cemiplimab.

What is the Condition Being Studied?

Objective

Recurrent Cutaneous Squamous Cell Carcinoma (a type of skin cancer that keeps returning)

Who Can Participate in the Study?

Key Eligibility

Adults with Squamous Cell Carcinoma that keeps coming back.
-The lesion must be about a half inch to one inch across

Age Group

Adults

What is Involved?

Description

If you choose to be in this study, you will:
-Get injected with the study drug (Cemiplimab) for 12 weeks
-Have a Blood draw
-Get a small biopsy of the skin
-Have an x-ray of your chest
-Give a urine sample

Study Details

Full Title

A Phase 1 Study of Pre-Operative Cemiplimab (REGN2810), Administered Intralesionally, for Patients with Recurrent Cutaneous Squamous Cell Carcinoma (CSCC) or Basal Cell Carcinoma ( BCC)

Principal Investigator